Evaluation of Risk Factors of Dyslipidemia in Renal Transplant Recipients "Urology Research Center- Tehran University of Medical Sciences"

Document Type : Research Paper


1 Resident of internal medicine,Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

2 Associate Professor of Nephrology, Sina Hospital, Tehran University of Medical Sciences; Tehran, Iran

3 Professor of Urology, SinaHospital, Tehran University of Medical Sciences; Tehran, Iran


Hyperlipidemia is an important metabolic disorder that is common among renal transplant recipients and contributes to the development of post-transplant accelerated coronary artery diseases. This study investigates the prevalence and risk factors of post transplant dyslipidemia in our center.
Materials and Methods
Retrospectively the records of 103 renal transplant recipients were evaluated at Sina Hospital in Tehran (Iran) between the years 2004 and 2007. The Patients’ demographic data, underlying renal disorder and immunosuppressive drugs regimen along with their laboratory data including total cholesterol (TC), Triglyceride (TG), serum creatinin (Cr) and fasting blood sugar were recorded.
Among the patients, there were 43 (41.7%) females and 60 (58.3%) males. The mean age (±SD) was 39.25± 13.9 years. The respective pre versus post transplantation lipid profile findings were: TC, 158±41 mg/dl versus 198±43 mg/dl, p<0.001; TG 152±78 mg/dl versus 195±83 mg/dl; p 
Renal transplant recipients are at a high risk of developing hyperlipidemia; therefore, they should be evaluated for risk factors.


1- Maeda H, Sakamoto K, Kashiwabara H, Hachisu T, Yamada H, Matsushita K, et al. Effect of hypertension,
hyperlipidemia and cyclosporine A therapy on long-term renal allograft survival. Transplant proc 1996; 28:1633.
2- Bittar AE, Ratcliffe PJ, Richardson AJ, Raine AEG, Jones L, Yudkin PL, et al. The prevalence of hyperlipidemia
in renal transplant recipients. Transplantation 1990; 50:987.
3-Catin SD, Pollocle AC, Catersan JR. Hyperlipidemia in renal transplant recipients: natural history and response to
treatment. Medicine 1994; 73:215-219.
4- Howard RJ, Patton PR, Reed AI, Hemming AW, Van Der Werf WJ, Pfaff WW, et al. The changing causes of
graft loss and death after kidney transplantation. Transplantation 2002; 73:1923-1928.
5- National kidney Foundation. Survival, mortality, and causes of death. Am J Kidney Dis 2003; 41: 151-164.
6-LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized
controlled trials. Jama 1999; 282:2340.
7- Dimeny E, Tufveson G, Lithell H, Larsson E, Siegbahn A, Fellstrom B. The influence of pre ransplant
lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993; 23:572.
8- Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia.
Kidney Int 1995; 48: s56.
9- Dimeny E, Walberg J, Lithell H, Fellstrom B. Hyperlipidemia in renal transplantation risk factor for long-term
graft outcome. Eur J clin invest 1995; 25:574.
10- Ballantyne CM, El Masri B, Morrisett JD, Torre-Amione G. Pathophysiology and treatment of lipid perturbation
after cardiac transplantation. Curr opin cardiol 1997; 12:153.
11- Ichimaru N, Takahara S, Kokado Y, Wang J-D, Hatori M, Kameoka H, et al. Changes in lipid metabolism and
effect of simvastain in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001;
12- Kanbay M, Yildirir A, Akcay A, Colak T, Ozdemir FN, Muderrisoglu H, et al. Effect of immunosuppressive
drugs on serum lipid levels in renal transplant recipients. Transplant proc 2006; 38:502-505.
13-Cattran DC, Steiner G, Wilson DR, Fenton SSA. Hyperlipidemia after renal transplantation: natural history and
pathophysiology. Ann intern Med 1979; 91:554-559.
14- Vathsala A, Weinberg RB, Schoenberg L, Grevel J, Goldstein RA, Van Buren CT, et al. Lipid abnormalities in
cyclosporine-prednisolone-treated renal transplant recipients. Transplantation 1989; 48:37-43.
15- Drueke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. Atherosclerosis and lipid disorders after
renal transplantation. Kidney int 1991; 39:S24-S28.
16- Tse KC, Lam MF, Yip PS, Li FK, Lai KN, Chan TM. A long term study on hyperlipidemia in stable renal
transplant recipients. Clin transplant 2004; 18:274-280.
17-Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS. Hyperlipidemia in renal transplant
recipients: natural history and response to treatment. Medicine 1994; 73:215.
18- Hu RH, Lee PH, Chung YC, Huang MT, Lee CS. Serum cholesterol and triglyceride levels in renal allograft
recipient in Taiwan. Transplant proc 1994; 26:2148.
19- Asberg A, Hartmann A, Fjeldsa E, Holdaas H. Atorvastatin improves endothelial function in renal transplant
recipient. Nephrol dial transplant 2001; 16:1920.
20- Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Nikiteas N, Kostakis A. Correlation between lipid
abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int urol
nephrol 2008; 40:521-527.
21- Kasiske BL, De Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, et al. Mammalian target of
rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J transplant 2008; 8:1384-1392.
22- Shivaswamy V, Stevens RB, Zephier R, Zephier M, Sun J, Groggel G, et al. Dyslipidemia can be controlled in
diabetic as well as non diabetic recipients after kidney transplant. Transplantation 2008; 85:1270-1276.